Henlius Biotech (02696) rose more than 5% intraday, and as of press time the stock was up 2.28% at HK$56.05, with turnover of HK$15.3369 million.
According to a post on the official WeChat account of Henlius Biotech (02696), at the annual meeting of the American Society for Radiation Oncology (ASTRO), two studies in the field of gastrointestinal oncology involving the company's independently developed innovative anti-PD-1 monoclonal antibody H drug Hansizhuang® were presented as posters.
The two studies are: the TORCH-C study on serplulimab combined with chemoradiotherapy for neoadjuvant treatment of pMMR-type high-risk locally advanced colon cancer (LACC), jointly initiated by Professor Cai Sanjun and Professor Zhang Zhen of Fudan University Shanghai Cancer Center, which explored an innovative neoadjuvant treatment model; and the study on serplulimab combined with chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ESCC), jointly initiated by Professor Fu Xiaolong and Professor Yu Wen of Shanghai Chest Hospital. These studies add an immunotherapy combined with stratified chemoradiotherapy treatment option to the field of gastrointestinal oncology, further demonstrating the clinical value and therapeutic potential of the H drug in this area.
The TORCH-C study released at this ASTRO meeting is a randomized phase II clinical trial targeting MSS/pMMR-type high-risk locally advanced colon cancer, evaluating the efficacy and safety of neoadjuvant short-course radiotherapy combined with the CAPOX regimen and serplulimab. Results showed that the pathological complete response (pCR) rate in the immunotherapy combined with short-course radiotherapy plus chemotherapy group reached 45.3%, more than four times higher than the chemotherapy-alone group (10%), providing a new treatment option for high-risk LACC patients. The data from this study were previously released at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.
Comments